Eli Lilly has reported new Phase 3b data showing that EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people living with moderate-to-severe atopic dermatitis affecting the hands and feet.

The announcement centers on a hard-to-treat anatomical presentation of the disease. Hand and foot involvement carries outsized functional consequences for patients, because the symptoms sit directly in the zones people use to work, dress, and interact. According to the company's statement, the Phase 3b results address those burdens directly, with improvements reported across skin clearance, itch, pain, and patient satisfaction — a composite of outcomes that spans both clinical signs and patient-reported measures.

The reported improvements were significant and rapid, according to the data released by Lilly. For clinicians, rapidity of onset is a meaningful attribute in this population: itch and pain localized to the palms and soles can be disabling enough to interfere with employment and basic daily tasks, so treatments that act quickly on these symptoms have practical value beyond aggregate efficacy scores.

The drug at the center of the data is lebrikizumab-lbkz, marketed by Lilly under the brand name EBGLYSS. The new results extend the molecule's evidence base into the specific hand and foot phenotype, a subset of moderate-to-severe atopic dermatitis that the announcement frames as an area of persistent unmet need.

Patient satisfaction appears as an explicit endpoint in the reported findings. That is worth noting for practice patterns, because satisfaction measures capture dimensions of treatment response — convenience, tolerability, and the subjective relief of symptoms — that conventional clinician-assessed endpoints can miss. In a condition where pain and itch in the hands and feet shape daily functioning, patient-reported improvement carries substantial weight in evaluating therapeutic value.

The data also cover itch and pain as distinct outcomes alongside skin clearance. In atopic dermatitis, clearance of visible lesions and resolution of symptoms do not always track together, and differential reporting of these endpoints gives clinicians a more granular picture of what the treatment achieved. Lilly's statement characterizes the improvements across all four domains — skin clearance, itch, pain, and patient satisfaction — as both significant and rapid.

For dermatologists who manage moderate-to-severe atopic dermatitis, the findings add to the evidence conversation around Lebrikizumab, an IL-13–targeting biologic in the Lilly portfolio, in a phenotype where topical therapy alone is often inadequate and where lesion location complicates both adherence and quality of life.

The headline data are drawn from a Phase 3b study design, which typically evaluates an already-characterized investigational or approved therapy in additional populations, regimens, or subgroups to refine its clinical profile. In this case, the Phase 3b program turned to patients with moderate-to-severe disease localized to the hands and feet, and the company reports significant and rapid improvement across the measured outcomes in that cohort.

Fuller presentation details — including specific effect sizes, responder rates, and the timepoints at which separation from control emerged — were not included in the headline announcement, and clinicians will want to examine those figures when the complete results are published or presented at a medical congress. The strength of any Phase 3b conclusion rests on those numbers: magnitude of clearance, degree of itch reduction, pain relief quantified, and the durability of patient satisfaction over the treatment period.

What the announcement establishes now is that Lilly has generated Phase 3b evidence in hand and foot atopic dermatitis and characterizes the results as significant and rapid across skin clearance, itch, pain, and patient satisfaction. As detailed data are released, dermatologists will be able to weigh lebrikizumab's performance in this functionally critical subtype against the broader treatment landscape and to judge its role for patients whose disease concentrates where it interferes most with daily life.